Kamada

Kamada Net Income

The Net Income of Kamada (KMDA) as of Nov 1, 2026 is 20.20 M USD. In the previous year, Net Income was 14.46 M USD — a change of 39.66% (higher).

Net Income

20.20 MUSD

YoY

39.66%

Last updated:

In 2025, Kamada's profit amounted to 20.20 M USD, a 39.66% increase from the 14.46 M USD profit recorded in the previous year.

The Kamada Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
8.28 M USD
Jan 1, 2024
14.46 M USD
Jan 1, 2025
20.20 M USD
Jan 1, 2026 (e)
27.54 M USD
Jan 1, 2027 (e)
33.26 M USD
Jan 1, 2028 (e)
37.30 M USD
Jan 1, 2029 (e)
44.13 M USD
Jan 1, 2030 (e)
54.51 M USD
The Kamada Net Income history
YEARNet IncomeYoY
est54.51 MUSD+23.53%
est44.13 MUSD+18.30%
est37.30 MUSD+12.14%
est33.26 MUSD+20.77%
est27.54 MUSD+36.36%
20.20 MUSD+39.66%
14.46 MUSD+74.58%
8.28 MUSD-456.92%
-2.32 MUSD+4.08%
-2.23 MUSD-113.01%
17.14 MUSD-22.97%
22.25 MUSD-0.20%
22.30 MUSD+223.08%
6.90 MUSD-202.50%
-6.73 MUSD-40.26%
-11.27 MUSD-10.81%
-12.64 MUSD-2,952.37%
443,000.00USD+70.38%
260,000.00USD-107.44%
-3.49 MUSD-76.98%
-15.17 MUSD-31.14%
-22.03 MUSD+77.03%
-12.45 MUSD-45.64%
-22.90 MUSD+663.19%
-3.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kamada Revenue

Kamada Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
142.52 M USD
9.73 M USD
8.28 M USD
Jan 1, 2024
160.95 M USD
20.05 M USD
14.46 M USD
Jan 1, 2025
180.46 M USD
26.23 M USD
20.20 M USD
Jan 1, 2026 (e)
202.96 M USD
35.66 M USD
27.54 M USD
Jan 1, 2027 (e)
228.16 M USD
42.96 M USD
33.26 M USD
Jan 1, 2028 (e)
248.25 M USD
47.98 M USD
37.30 M USD
Jan 1, 2029 (e)
266.22 M USD
57.44 M USD
44.13 M USD
Jan 1, 2030 (e)
282.73 M USD
70.73 M USD
54.51 M USD

Kamada Margins

Kamada stock margins

The Kamada margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kamada. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kamada.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
38.94 %
6.83 %
5.81 %
Jan 1, 2024
43.47 %
12.46 %
8.99 %
Jan 1, 2025
42.34 %
14.54 %
11.19 %
Jan 1, 2026 (e)
42.34 %
17.57 %
13.57 %
Jan 1, 2027 (e)
42.34 %
18.83 %
14.58 %
Jan 1, 2028 (e)
42.34 %
19.33 %
15.03 %
Jan 1, 2029 (e)
42.34 %
21.58 %
16.57 %
Jan 1, 2030 (e)
42.34 %
25.02 %
19.28 %

Kamada Stock analysis

What does Kamada do? Kamada Ltd is an Israel-based company specializing in the development and marketing of biopharmaceutical products for humans and animals. The company was founded in 1990 by a team of experienced executives and scientists from the biotech industry. Since its inception, Kamada has become a global leader in plasma fractionation and the production of antibodies and enzymes. The company is listed on the NASDAQ and the Tel Aviv Stock Exchange and has over 450 employees in its facilities in Israel and the USA. Kamada's business model is based on combining innovative science and technology to develop products and therapies for rare and severe diseases. The company is constantly working to improve its production processes to deliver more efficient and cost-effective products. Kamada operates in three divisions: human therapeutics, veterinary medicine, and plasma research. The human therapeutics division develops and markets products for the treatment of diseases such as alpha-1 antitrypsin deficiency, immunoglobulin deficiency, hemophilia, and other serious conditions. The veterinary medicine division offers products for the treatment of diseases in dogs, horses, and cows to veterinary professionals. The plasma research division focuses on developing technologies for the production of plasma derivatives and discovering new applications for plasma proteins. Kamada has a wide range of products on the market, including its flagship product Glassia, which is used to treat alpha-1 antitrypsin deficiency, a rare genetic disease that can affect the lungs. The company also produces intravenous immunoglobulin preparations for the treatment of immune deficiencies and other immune system disorders, as well as recombinant factor VIII for the treatment of hemophilia. In veterinary medicine, Kamada offers products such as Equine Seramune, designed for horses and used to treat life-threatening infections caused by bacteria found in the intestines of horses. The company also produces products for the treatment of mastitis, an infection of the milk ducts in cows, and gastrointestinal tract infections in dogs. Kamada takes pride in playing a leading role in plasma research and technology. The company's research has resulted in groundbreaking technologies that allow for the faster and more cost-effective production of important plasma proteins than was previously possible. Kamada works closely with other research institutions and companies to collaborate on solutions for severe and rare diseases. Over the years, Kamada has received numerous awards and recognition for its groundbreaking research and development work. The company is committed to continuing to develop innovative products and therapies to improve the lives of patients with rare and severe diseases. Overall, Kamada Ltd has experienced remarkable growth in recent years. It is a company that plays a leading role in the market for biopharmaceutical products based on top-notch scientific research and efficient technology. In the future, Kamada will undoubtedly continue to develop groundbreaking products and therapies to improve the lives of patients worldwide. Kamada is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Kamada's Profit Margins

The profit margins of Kamada represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Kamada's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Kamada's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Kamada's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Kamada’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Kamada stock

Net Income of Kamada is 20.20 M USD in 2025.

Net Income of Kamada changed from 14.46 M USD to 20.20 M USD, representing a 39.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Kamada since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Kamada historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Kamada

All Key Metrics — Kamada